rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Delcath Systems, Inc.

DCTH · Nasdaq

Health CareMedical DevicesLeading

DCTH stood above a rising 150-day average in 23 of the last 52 weekly readings, including each of the last 23 weeks. It is 11.1% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
23 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$438K
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
116 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$290KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Roger Marshall House: U.S. House ClerkKS01sold$1k–$15k9 Jun 2017filed 6 Aug 2018

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Sandra PennellChief Financial Officerbought5,533at $9.046 Mar 2026filed 6 Mar 2026
Gerard J. MichelCHIEF EXECUTIVE OFFICERbought11,200at $8.962 Mar 2026filed 3 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders116+1 on the quarter
New · exited22 · 21
Reported value$218.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rosalind Advisors, Inc.unchanged · filed 14 Aug 20263,300,389$41.6M00.0%
BlackRock, Inc.added · filed 7 Aug 20262,706,802$34.1M+922,336+51.7%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,221,247$15.4M-108,041−8.1%
Propel Bio Management, LLCreduced · filed 13 Aug 2026871,460$11.0M-108,238−11.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026733,115$9.2M+41,084+5.9%
STATE STREET CORPadded · filed 7 Aug 2026679,280$8.6M+14,852+2.2%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026566,371$7.1M-21,684−3.7%
Divisadero Street Capital Management, LPunchanged · filed 14 Aug 2026499,796$6.3M00.0%
MORGAN STANLEYadded · filed 13 Aug 2026407,983$5.1M+22,459+5.8%
ExodusPoint Capital Management, LPadded · filed 14 Aug 2026359,884$4.5M+323,916+900.6%
31 Mar 2023 – 30 Jun 2026
2369115Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Rosalind Advisors, Inc. Company insiderDirector · last 13 Oct 202614 · 0
Bridget A. Martell Company insiderDirector · last 13 May 20260 · 0
Elizabeth Czerepak Company insiderDirector · last 13 May 20260 · 0
Gil Aharon Company insiderDirector · last 13 May 20263 · 0
John Richard Sylvester Company insiderDirector · last 13 May 20262 · 0
Steven A. J. Salamon Company insiderDirector · last 13 May 202617 · 0
Sandra Pennell Company insiderChief Financial Officer · last 6 Mar 20262 · 0
Gerard J. Michel Company insiderCHIEF EXECUTIVE OFFICER · last 2 Mar 202613 · 0
David L. Hoffman Company insiderGEN'L COUNSEL, CCO & SECY · last 17 Feb 20261 · 0
Kevin Muir Company insiderGM INTERVENTIONAL ONCOLOGY · last 17 Feb 20260 · 0
Martha S. Rook Company insiderCHIEF OPERATING OFFICER · last 17 Feb 20260 · 0
Vojo Vukovic Company insiderCHIEF MEDICAL OFFICER · last 17 Feb 20262 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202586.2%
Operating profit marginFY 2025 · to 31 Dec 20250.8%
Free cash flow marginFY 2025 · to 31 Dec 202524.6%
Return on capital employedFY 2025 · to 31 Dec 20250.6%
Cash conversionFY 2025 · to 31 Dec 2025834%
Research spendFY 2025 · to 31 Dec 202534.3%
Share count trendFY 2025 · to 13 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$43.5M
Free cash flowFY 2025 · to 31 Dec 2025$21.0M

Analyst forecasts

No analyst forecasts yet.